These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 6215992)

  • 41. [Rubella vaccine coverage and seroprotection in 11-year-old children in the Indre-et-Loire department].
    Bourderioux C; Hubert B; Vol S; Feyt M; Drucker J; Tichet J
    Arch Pediatr; 1994 Oct; 1(10):941-3. PubMed ID: 7842078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Rubella antibody determination in pregnancy--effectiveness of a screening program].
    Robra BP; Müller HE; Fingscheidt E
    Offentl Gesundheitswes; 1981 Nov; 43(11):559-63. PubMed ID: 6212800
    [No Abstract]   [Full Text] [Related]  

  • 43. Study of young women vaccinated against rubella virus for 10 years in Taiwan.
    Lin DB; Kao CL; Lee CY
    Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):707-14. PubMed ID: 9253871
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Live attenuated rubella virus vaccine in a private pediatric practice.
    Nickey LN; Huchton P; Rogers PL
    Tex Med; 1973 Feb; 69(2):93-8. PubMed ID: 4734589
    [No Abstract]   [Full Text] [Related]  

  • 45. [Clinical trial of the Cendehill strain of live, attenuated rubella virus vaccine].
    Page W; Fattorini A
    Minerva Med; 1970 Apr; 61(30 Suppl):1601-12. PubMed ID: 5439726
    [No Abstract]   [Full Text] [Related]  

  • 46. Rubella vaccine in the People's Republic of China.
    Han YR; Zhao K; Gong YX; Hao SL; Wang SZ; Wang CT
    Rev Infect Dis; 1985; 7 Suppl 1():S79. PubMed ID: 4001739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rubella: seroepidemiology and vaccination over a ten-year period in central Italy.
    Midulla M; Assensio AM; Balducci L; Vanni O; Chiesa C
    Ann Sclavo; 1981; 23(2):127-42. PubMed ID: 7325729
    [No Abstract]   [Full Text] [Related]  

  • 48. Vaccination with RA 27-3 rubella vaccine. Persistence of immunity and resistance to challenge after two years.
    Liebhaber H; Ingalls TH; Le Bouvier GL; Horstmann DM
    Am J Dis Child; 1972 Feb; 123(2):133-6. PubMed ID: 4554549
    [No Abstract]   [Full Text] [Related]  

  • 49. Persistence of antibody induced by rubella vaccine (Wistar RA 27/3 strain) after six years.
    Hillary IB; Freestone DS
    J Hyg (Lond); 1975 Dec; 75(3):407-11. PubMed ID: 1059708
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immune status of a school-population sample 5 years after antirubella vaccination].
    Quaglio P; Dattoli A; Mantovani G
    G Batteriol Virol Immunol; 1982; 75(7-12):233-8. PubMed ID: 7188256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Certainty instead of probability--a practical and economic method for conducting directed and controlled mass rubella vaccinations through public health departments].
    Leidel J; Leidel S; Zippel C; Federmann G; Wiegand G; Eggers HJ
    Offentl Gesundheitswes; 1981 Nov; 43(11):564-8. PubMed ID: 6212801
    [No Abstract]   [Full Text] [Related]  

  • 52. [Evaluation of the immune status in a female population sample 10 years after rubella vaccination].
    Becchi A; Fornero M; Mantovani G
    Nuovi Ann Ig Microbiol; 1985; 36(4):305-11. PubMed ID: 3842769
    [No Abstract]   [Full Text] [Related]  

  • 53. [Selective and controlled mass rubella vaccination - experiences with an economical method (author's transl)].
    Zippel C; Federmann G; Leidel J; Eggers HJ
    Immun Infekt; 1982 Mar; 10(2):69-75. PubMed ID: 7040210
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The rubella immunity survey of unmarried school-aged women in Taipei and feasibility study of rubella vaccination].
    Wu LC; Yen MH; Ng HT; Yuan FJ
    Zhonghua Yi Xue Za Zhi (Taipei); 1987 Sep; 40(3):309-16. PubMed ID: 3502849
    [No Abstract]   [Full Text] [Related]  

  • 55. [Rubella antibody in a sample of Foggia (Italy) population (author's transl)].
    Telesforo P; D'Errico A; Rosenberg R
    Ann Sclavo; 1979; 21(4):413-8. PubMed ID: 554544
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Controlled rubella vaccination at the Stuttgart Public Health Center].
    Fischer D; Beyer von Voigt T; Bontemps M
    Offentl Gesundheitswes; 1991 Apr; 53(4):161-2. PubMed ID: 1830944
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Late seroconversion following HPV-77, DE5 rubella virus vaccine.
    Wilkins J
    Am J Obstet Gynecol; 1975 Apr; 121(7):998-1002. PubMed ID: 1115189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Waning antibodies in measles and rubella vaccinees--a longitudinal study.
    Kremer JR; Schneider F; Muller CP
    Vaccine; 2006 Mar; 24(14):2594-601. PubMed ID: 16427163
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccination against rubella in Britain: benefits and risks.
    Freestone DS
    Dev Biol Stand; 1979; 43():339-48. PubMed ID: 520680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The anti-rubella immune state of the adult female population of Local Health Unit 26 of the Piedmont Region. Prospects for a vaccination campaign].
    Novara O; Paggi GC; Massa R; Falone L; Marinone GC
    Minerva Med; 1984 Sep; 75(34):1939-45. PubMed ID: 6483251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.